Advertisement
The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

LAB Research under review by TSX for continued listing on exchange

February 3, 2011 8:45 am | by The Associated Press | News | Comments

LAB Research Inc. (TSX:LRI) is under review by the Toronto Stock Exchange to ensure it is meeting the requirements of a continued listing.

Dollars + STEM Education = Job Creation

February 3, 2011 8:36 am | by Society of Manufacturing Engineers | News | Comments

DEARBORN, Mich., January 31, 2011 — In a recent study, the Kauffman Foundation found that in any given year, the top-performing one percent of firms is generating roughly 40 percent of all new jobs. The SME Education Foundation accelerated its efforts through relationships with this...

Microchips moves osteoporosis device into trial

February 3, 2011 8:35 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Some 18 years after MIT professor Robert Langer first envisioned using an implantable reservoir as a drug delivery device, one of his companies, MicroCHIPS Inc. of Bedford, announced today that it is initiating a clinical study of a device that delivers a peptide over the course of months...

Advertisement

Carrot Medical Reports 2010 Growth in Sales and Financing, Optimism for 2011

February 3, 2011 7:33 am | by Bio-Medicine.Org | News | Comments

BOSTON, Feb. 3, 2011 /- Carrot Medical, a leading designer of integrated medical imaging display systems, has announced results for 2010. During the year, Carrot Medical achieved significant growth in sales, an expansion of sales channels and secured additional private financing. Carrot...

TOPICS:

Curemark Hosts New York Senator Kirsten Gillibrand

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

RYE, N.Y., Feb. 3, 2011 /- Curemark, LLC , ( www.curemark.com ), a drug research and development company focused on the treatment of neurological diseases, recently hosted New York Senator Kirsten Gillibrand as she announced a new proposal to spur innovation and job creation, locally and...

TOPICS:

Hospira Announces FDA Approval of Topotecan Injection

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

LAKE FOREST, Ill., Feb. 3, 2011 /- Hospira, Inc. (NYSE: HSP ), the world leader in generic injectable pharmaceuticals, today announced U.S. Food and Drug Administration (FDA) approval of Topotecan Injection, the first solution formulation of the oncology drug approved in the United...

TOPICS:

SkinMedica Launches Redness Relief CalmPlexâ„¢

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

CARLSBAD, Calif., Feb. 3, 2011 /- SkinMedica, Inc., the fastest-growing professional skin care company in the United States, today announced that it is introducing a new, fast-acting anti-redness product, Redness Relief CalmPlex™—the biggest innovation in redness in over two...

TOPICS:

Dendreon Announces Exercise and Closing of Overallotment Option

February 3, 2011 7:32 am | by Bio-Medicine.Org | News | Comments

SEATTLE, Feb. 3, 2011 /- Dendreon Corporation (Nasdaq: DNDN ) today announced that the underwriter in its previously announced public offering of 2.875% convertible senior notes due January 15, 2016 (the "Notes") exercised and closed on its overallotment option in full to purchase an...

TOPICS:
Advertisement

Missouri Baptist Medical Center - Only Non-Teaching Hospital in Region to Offer Colorectal Cancer Patients Robotic Surgery

February 3, 2011 7:30 am | by Bio-Medicine.Org | News | Comments

ST. LOUIS, Feb. 3, 2011 /- Missouri Baptist Medical Center now provides patients with a new, minimally invasive surgical treatment option for colorectal cancer – robotic surgery with the da Vinci®-S™ Surgical System.  Eric D. Lederman, MD, a board certified general...

TOPICS:

Summary Box: CVS Caremark 4th-quarter profit slips

February 3, 2011 6:45 am | by The Associated Press | News | Comments

THE RESULTS: CVS Caremark Corp. said its fourth-quarter profit slipped because of business lost by its Caremark pharmacy benefits management unit. The company expects better results in 2011, but said operating income at Caremark will continue to decline.THE OUTLOOK: Caremark's income is expected to...

Wire Compound in Medical Elastomer Range Fully Compliant With Medical Requirements

February 3, 2011 6:42 am | Product Releases | Comments

The first wire and cable compound in the Medalist family of medical elastomers is formulated and produced in accordance with stringent medical-industry requirements yet draws on technology with a long track record of success...

CVS Caremark 4Q profit falls 2 percent

February 3, 2011 5:45 am | by The Associated Press | News | Comments

Drugstore chain and pharmacy benefits manager CVS Caremark Corp. said Thursday that its profit fell 2 percent in the fourth quarter on lower revenue because of client losses and fewer Medicare prescription drug program members.The company also offered an estimate for adjusted earnings for this...

Lilly and JDRF partner to fund regenerative medicine research in type 1 diabetes

February 3, 2011 5:36 am | by EurekAlert | News | Comments

(Juvenile Diabetes Research Foundation International) Eli Lilly and Company and the Juvenile Diabetes Research Foundation today announced that they have signed an agreement to fund early-stage research that could enable patients with type 1 diabetes to regenerate insulin-producing...

TOPICS:

Adapting technology to elderly people

February 3, 2011 5:36 am | by EurekAlert | News | Comments

(EUREKA) With the numbers of people aged 65 and over growing, the costs to the state to care for or assist them are set to continue rising across the European Union. With this backdrop, two companies have combined their differing expertise, with the help of Eureka funding, to...

TOPICS:

Concert Pharmaceuticals, Walter Reed partner on seizure treatment

February 3, 2011 5:32 am | by Mass High Tech: The Journal of New England Technology | News | Comments

Concert Pharmaceuticals Inc. today announced that it has signed an agreement to work with the Walter Reed Army Institute of Research to conduct preclinical testing of a Concert drug compound in treating seizures stemming from traumatic brain injuries.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading